Acyclovir suppression to prevent recurrent genital herpes at delivery

Laurie L. Scott, L. M. Hollier, D. McIntire, P. J. Sanchez, G. L. Jackson, G. D. Wendel

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objective: To determine if suppressive acyclovir near term decreased the frequency of clinical recurrences at delivery in women with recurrent genital herpes simplex virus (HSV) infection. Methods: We conducted a prospective, double-blind, randomized trial in 234 women with recurrent genital herpes. Women with genital infection of any frequency were enrolled. Patients received either suppressive oral acyclovir 400 mg three times daily or an identical placebo after 36 weeks' gestation. Clinical lesions were identified, and HSV cultures were obtained at delivery. The frequencies of clinical and subclinical HSV recurrences at delivery were evaluated. Results: Six percent of patients treated with acyclovir, and 14% of patients treated with placebo had clinical HSV at delivery (p = 0.046). No patients in the acyclovir group had positive HSV cultures, compared with 6% of placebo-treated patients (p = 0.029). There was no significant difference in subclinical HSV shedding in the acyclovir group (0%) compared with the placebo-treated group (3%) (p = 0.102). Conclusions: Suppressive acyclovir therapy significantly decreased the incidence of clinical genital herpes and the overall incidence of HSV excretion at delivery in patients with previous herpes infection.

Original languageEnglish (US)
Pages (from-to)71-77
Number of pages7
JournalInfectious Diseases in Obstetrics and Gynecology
Volume10
Issue number2
StatePublished - 2002

Fingerprint

Herpes Genitalis
Acyclovir
Simplexvirus
Placebos
Virus Shedding
Recurrence
Incidence
Infection
Pregnancy

Keywords

  • Antiviral agents
  • Cesarean delivery
  • Herpes genitalis
  • Herpes simplex
  • Pregnancy complications, infectious

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Dermatology

Cite this

Scott, L. L., Hollier, L. M., McIntire, D., Sanchez, P. J., Jackson, G. L., & Wendel, G. D. (2002). Acyclovir suppression to prevent recurrent genital herpes at delivery. Infectious Diseases in Obstetrics and Gynecology, 10(2), 71-77.

Acyclovir suppression to prevent recurrent genital herpes at delivery. / Scott, Laurie L.; Hollier, L. M.; McIntire, D.; Sanchez, P. J.; Jackson, G. L.; Wendel, G. D.

In: Infectious Diseases in Obstetrics and Gynecology, Vol. 10, No. 2, 2002, p. 71-77.

Research output: Contribution to journalArticle

Scott, LL, Hollier, LM, McIntire, D, Sanchez, PJ, Jackson, GL & Wendel, GD 2002, 'Acyclovir suppression to prevent recurrent genital herpes at delivery', Infectious Diseases in Obstetrics and Gynecology, vol. 10, no. 2, pp. 71-77.
Scott, Laurie L. ; Hollier, L. M. ; McIntire, D. ; Sanchez, P. J. ; Jackson, G. L. ; Wendel, G. D. / Acyclovir suppression to prevent recurrent genital herpes at delivery. In: Infectious Diseases in Obstetrics and Gynecology. 2002 ; Vol. 10, No. 2. pp. 71-77.
@article{d076cadc47b3441d893a325be01fc559,
title = "Acyclovir suppression to prevent recurrent genital herpes at delivery",
abstract = "Objective: To determine if suppressive acyclovir near term decreased the frequency of clinical recurrences at delivery in women with recurrent genital herpes simplex virus (HSV) infection. Methods: We conducted a prospective, double-blind, randomized trial in 234 women with recurrent genital herpes. Women with genital infection of any frequency were enrolled. Patients received either suppressive oral acyclovir 400 mg three times daily or an identical placebo after 36 weeks' gestation. Clinical lesions were identified, and HSV cultures were obtained at delivery. The frequencies of clinical and subclinical HSV recurrences at delivery were evaluated. Results: Six percent of patients treated with acyclovir, and 14{\%} of patients treated with placebo had clinical HSV at delivery (p = 0.046). No patients in the acyclovir group had positive HSV cultures, compared with 6{\%} of placebo-treated patients (p = 0.029). There was no significant difference in subclinical HSV shedding in the acyclovir group (0{\%}) compared with the placebo-treated group (3{\%}) (p = 0.102). Conclusions: Suppressive acyclovir therapy significantly decreased the incidence of clinical genital herpes and the overall incidence of HSV excretion at delivery in patients with previous herpes infection.",
keywords = "Antiviral agents, Cesarean delivery, Herpes genitalis, Herpes simplex, Pregnancy complications, infectious",
author = "Scott, {Laurie L.} and Hollier, {L. M.} and D. McIntire and Sanchez, {P. J.} and Jackson, {G. L.} and Wendel, {G. D.}",
year = "2002",
language = "English (US)",
volume = "10",
pages = "71--77",
journal = "Infectious Diseases in Obstetrics and Gynecology",
issn = "1064-7449",
publisher = "Hindawi Publishing Corporation",
number = "2",

}

TY - JOUR

T1 - Acyclovir suppression to prevent recurrent genital herpes at delivery

AU - Scott, Laurie L.

AU - Hollier, L. M.

AU - McIntire, D.

AU - Sanchez, P. J.

AU - Jackson, G. L.

AU - Wendel, G. D.

PY - 2002

Y1 - 2002

N2 - Objective: To determine if suppressive acyclovir near term decreased the frequency of clinical recurrences at delivery in women with recurrent genital herpes simplex virus (HSV) infection. Methods: We conducted a prospective, double-blind, randomized trial in 234 women with recurrent genital herpes. Women with genital infection of any frequency were enrolled. Patients received either suppressive oral acyclovir 400 mg three times daily or an identical placebo after 36 weeks' gestation. Clinical lesions were identified, and HSV cultures were obtained at delivery. The frequencies of clinical and subclinical HSV recurrences at delivery were evaluated. Results: Six percent of patients treated with acyclovir, and 14% of patients treated with placebo had clinical HSV at delivery (p = 0.046). No patients in the acyclovir group had positive HSV cultures, compared with 6% of placebo-treated patients (p = 0.029). There was no significant difference in subclinical HSV shedding in the acyclovir group (0%) compared with the placebo-treated group (3%) (p = 0.102). Conclusions: Suppressive acyclovir therapy significantly decreased the incidence of clinical genital herpes and the overall incidence of HSV excretion at delivery in patients with previous herpes infection.

AB - Objective: To determine if suppressive acyclovir near term decreased the frequency of clinical recurrences at delivery in women with recurrent genital herpes simplex virus (HSV) infection. Methods: We conducted a prospective, double-blind, randomized trial in 234 women with recurrent genital herpes. Women with genital infection of any frequency were enrolled. Patients received either suppressive oral acyclovir 400 mg three times daily or an identical placebo after 36 weeks' gestation. Clinical lesions were identified, and HSV cultures were obtained at delivery. The frequencies of clinical and subclinical HSV recurrences at delivery were evaluated. Results: Six percent of patients treated with acyclovir, and 14% of patients treated with placebo had clinical HSV at delivery (p = 0.046). No patients in the acyclovir group had positive HSV cultures, compared with 6% of placebo-treated patients (p = 0.029). There was no significant difference in subclinical HSV shedding in the acyclovir group (0%) compared with the placebo-treated group (3%) (p = 0.102). Conclusions: Suppressive acyclovir therapy significantly decreased the incidence of clinical genital herpes and the overall incidence of HSV excretion at delivery in patients with previous herpes infection.

KW - Antiviral agents

KW - Cesarean delivery

KW - Herpes genitalis

KW - Herpes simplex

KW - Pregnancy complications, infectious

UR - http://www.scopus.com/inward/record.url?scp=0036379099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036379099&partnerID=8YFLogxK

M3 - Article

C2 - 12530483

AN - SCOPUS:0036379099

VL - 10

SP - 71

EP - 77

JO - Infectious Diseases in Obstetrics and Gynecology

JF - Infectious Diseases in Obstetrics and Gynecology

SN - 1064-7449

IS - 2

ER -